Torrent Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Torrent Pharmaceuticals Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Torrent Pharmaceuticals Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Torrent Pharma from all sources in a single place.

Torrent Pharmaceuticals Ltd.

26 May 2026, 12:00AM

4452.10

-2.64%

Torrent Pharma

Buy: Torrent Pharmaceuticals Ltd.

Target

ICICI Direct

About the stock: Incorporated in 1959, Torrent remains a key play in branded generics (~75% of sales) with strong India franchise and growing exports traction. While Branded franchisee comprises of India, Brazil and some export markets, the...

Torrent Pharma has gained 40.24% in the last 1 Year

Torrent Pharmaceuticals Ltd.

25 May 2026, 10:54AM

4452.10

-2.64%

Torrent Pharma rises 5% on Q4 beat; brokerages divided on JBCP integration

Business Standard

Torrent Pharma's revenue from operations rose 42 per cent Y-o-Y to 4,197 crore in Q4FY26 from 2,959 crore in Q4FY25

ICICI Direct increased Buy price target of Torrent Pharmaceuticals Ltd. to 5100.0 on 26 May, 2026.

Torrent Pharmaceuticals Ltd.

25 May 2026, 12:00AM

4452.10

-2.64%

BP Equities Q4FY26 Result Update Torrent Pharmaceuticals Ltd.

Results Update: Torrent Pharmaceuticals Ltd.

BP Wealth

...

ICICI Direct increased Buy price target of Torrent Pharmaceuticals Ltd. to 5100.0 on 26 May, 2026.

Torrent Pharmaceuticals Ltd.

23 May 2026

4452.10

-2.64%

Company Update

Torrent Pharmaceuticals Ltd - 500420 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Annual Secretarial Compliance Report for 2025-26

pdf

Torrent Pharmaceuticals Ltd.

23 May 2026

4452.10

-2.64%

After early Semaglutide lead, Torrent Pharma eyes US liver drug Resmetirom for India launch

Business Line

Resmetirom is the first approved therapy in the US specifically for MASH, earlier known as NASHa progressive fatty liver disease linked to obesity, diabetes and poor metabolic health

ICICI Direct increased Buy price target of Torrent Pharmaceuticals Ltd. to 5100.0 on 26 May, 2026.

Torrent Pharmaceuticals Ltd.

22 May 2026

4452.10

-2.64%

Torrent Pharmaceuticals Results Earnings Call for Q4FY26 & Full Year

Conference Call with Torrent Pharmaceuticals Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

audio

Torrent Pharmaceuticals Ltd.

22 May 2026

4452.10

-2.64%

Torrent Pharma Q4 profit falls 21.9% on high expenses despite revenue boost

Business Standard

Torrent Pharma's Q4 profit dropped 22% as JB Pharma integration costs pushed up expenses, despite strong growth in semaglutide-led revenues

Torrent Pharmaceutic.. has an average target of 4302.57 from 8 brokers.

Torrent Pharma Q4 profit drops 26% on JB Pharma acquisition costs, severance compensation

Business Line | 22 May 2026

Torrent Pharmaceuticals Ltd.

22 May 2026

4452.10

-2.64%

Torrent Pharma Q4 profit falls 27% to 364 cr due to exceptional item outgo

Business Standard

Torrent Pharmaceuticals Ltd on Friday reported a 27 per cent decline in profit after tax to Rs 364 crore in the fourth quarter ended March 31, 2026, impacted by exceptional items outgo. The company had posted a net profit of Rs 498 crore in the corresponding period of the preceding fiscal, Torrent Pharmaceuticals said in a statement. Total revenue from operations in the fourth quarter of FY26 stood at Rs 4,197 crore as against Rs 2,959 crore in the year-ago period, it added. The company had exceptional items outgo of Rs 66 crore in the quarter, as per the regulatory filing. The board has recommended a final dividend of Rs 9 per equity share of a face value of Rs 5 each. The pharma company's India business revenue stood at Rs 2,215 crore, up 43 per cent, in the quarter, while the Brazil revenue came in at Rs 455 crore, up by 30 per cent. Revenue from the US business stood at Rs 396 crore, up 31 per cent year-on-year, Torrent Pharma said. For FY26, net profit increased to Rs 2,138